Semigran, Marc J.

Apoptosis in Myocytes in End-Stage Heart Failure

Narula, J., Haider, N., Virmani, R., DiSalvo, T. G., Kolodgie, F. D., Hajjar, R. J., Schmidt, U., Semigran, M. J., Dec, G. W., & Khaw, B.-A. (1996) · New England Journal of Medicine

Cell death mechanisms and regulationCardiac Fibrosis and Remodeling

Cited by 1,430

Metabolic signatures of exercise in human plasma

Lewis, G. D., Farrell, L., Wood, M. J., Martinovic, M., Arany, Z., Rowe, G. C., Souza, A., Cheng, S., McCabe, E. L., Yang, E., et al. (2010) · Science Translational Medicine

Metabolomics and Mass Spectrometry StudiesCardiovascular and exercise physiology

Cited by 432

Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study

Givertz, M. M., Anstrom, K. J., Redfield, M. M., Deswal, A., Haddad, H., Butler, J., Tang, W. H. W., Dunlap, M. E., LeWinter, M. M., Mann, D. L., et al. (2015) · Circulation

Gout, Hyperuricemia, Uric AcidHeart Failure Treatment and Management

Cited by 296

Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes

Lindman, B. R., Dávila-Román, V. G., Mann, D. L., McNulty, S., Semigran, M. J., Lewis, G. D., de las Fuentes, L., Joseph, S. M., Vader, J., Hernandez, A. F., et al. (2014) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 209